Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | CCR9 | P51686 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700299 | 0.83 | SMN1; SMN2 (0.50) | LOXLOXL2S1PR1LMNASMN1; SMN2 | |
| SCHEMBL3467323 | 0.83 | LOX (0.46) | LOXLOXL2S1PR1LMNASMN1; SMN2 | |
| SCHEMBL25270609 | 0.82 | JAK2 (0.39) | LMNASMN1; SMN2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL30232338 | 0.81 | S1PR1 (0.53) | LOXLOXL2S1PR1LMNASMN1; SMN2 | |
| SCHEMBL25227918 | 0.81 | ALDH1A1 (0.42) | ALDH1A1HSD17B10TDP1TRPV4 | |
| SCHEMBL23833452 | 0.76 | ALDH1A1 (0.34) | ALDH1A1HSD17B10TDP1KDM4E | |
| SCHEMBL27285412 | 0.76 | PTGS2 (0.39) | CNR1 | |
| SCHEMBL3449694 | 0.75 | UHRF1 (0.46) | ALDH1A1HSD17B10TDP1CCR9 | |
| SCHEMBL30410070 | 0.75 | UHRF1 (0.46) | ALDH1A1HSD17B10TDP1CCR9 | |
| SCHEMBL724036 | 0.74 | TDP1 (0.46) | LOXLOXL2ALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-4436661-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023094827-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | CACNA1A, CACNA1E, CACNA1S | LOX 2469/4885LOXL2 1001/4885S1PR1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.